Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome Transcript (opens in new tab)
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi Syndrome June 13, 2026 9:00 AM...
Read the original article